January 12, 2021 -- Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.
According to the company, the workflow can screen up to 100,000 cells and functionally test cells with highly sensitive cell-based assays. The workflow captures reexpressed molecules without the need for gene synthesis and bacterial cloning and increases the possibilities of success to access hard-to-hit targets.
The workflow uses the company's OptoSeq barcoded B-cell receptors, heavy and light chain antibody genes can be sequenced by DNA fragmentation, next-generation sequencing, and/or bioinformatics analysis. The results from the workflow can be integrated on the Berkeley Lights system to further accelerate candidates to market with antibody engineering and cell line development.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
